Francesco Roberto Simonetti

Francesco Roberto Simonetti

Auto-generated profile, based on publicly available information

Francesco Roberto Simonetti

Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2014 in Science
Verified
Journal Article
Closed access
PDF file
FMF. Maldarelli
F. Maldarelli
XWX. Wu
X. Wu
LSL. Su
L. Su
FSF. R. Simonetti
F. R. Simonetti
WSW. Shao
W. Shao
SHStephen Hughes
Stephen Hughes
For HIV: Location, location, location: HIV-infected cells linger even in the face of therapy, and this persistence, termed the latent reservoir, is a major hurdle for curing HIV. HIV integrates itself into the DNA of its host cells. Could that affect the latent reservoir? To find out, Maldarelli et al. drew blood from five HIV patients on antiretroviral therapy and analyzed sites where HIV had inserted itself into the blood cells' DNA (see the Perspective by Margolis and Bushman). In many cases, these sites were not random; HIV often weaseled its way into genes that help cells grow and proliferate. Where HIV integrates into the host genome may thus determine the size of the latent reservoir. Science , this issue p. 179 ; see also p. 143

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
KBKatherine M. Bruner
Katherine M. Bruner
ZWZheng Wang
Zheng Wang
FSFrancesco R. Simonetti
Francesco R. Simonetti
ABAlexandra M. Bender
Alexandra M. Bender
KKKyungyoon J. Kwon
Kyungyoon J. Kwon
RSRobert F. Siliciano
Robert F. Siliciano

8 February 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FSFrancesco R. Simonetti
Francesco R. Simonetti
MSMichele D. Sobolewski
Michele D. Sobolewski
EFElizabeth Fyne
Elizabeth Fyne
WSWei Shao
Wei Shao
JSJonathan Spindler
Jonathan Spindler
Frank MaldarelliFrank Maldarelli
Frank Maldarelli
Reservoirs of infectious HIV-1 persist despite years of combination antiretroviral therapy and make curing HIV-1 infections a major challenge. Most of the proviral DNA resides in CD4+T cells. Some of these CD4+T cells are clonally expanded; most of the proviruses are defective. It is not known if any of the clonally expanded cells carry replication-competent proviruses. We report that a highly expanded CD4+ T-cell clone contains an intact provirus. The highly expanded clone produced infectious virus that was detected as persistent plasma viremia during cART in an HIV-1–infected patient who had squamous cell cancer. Cells containing the intact provirus were widely distributed and significantly enriched in cancer metastases. These results show that clonally expanded CD4+T cells can be a reservoir of infectious HIV-1. Significance Reservoirs of HIV-infected cells persist during antiretroviral therapy, and understanding persistence is essential to develop HIV curative strategies. During replication, HIV integrates into the host genome; most proviruses are not infectious, but some with replication-competent HIV persist. Cells with integrated HIV can proliferate, potentially expanding the reservoir, but whether cells with replication-competent HIV actually undergo expansion is unknown. HIV reactivation is often lethal to infected cells, and others have reported finding no replication-competent HIV in expanded populations. We describe a highly expanded clone containing infectious HIV that was the source of viremia for years in a patient. Clonally expanded populations can represent a long-lived reservoir of HIV. Curative strategies will require targeting this persistence mechanism.

1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
FSFrancesco R. Simonetti
Francesco R. Simonetti
HZHao Zhang
Hao Zhang
GSGarshasb P. Soroosh
Garshasb P. Soroosh
JDJiayi Duan
Jiayi Duan
KRKyle Rhodehouse
Kyle Rhodehouse
RSRobert F. Siliciano
Robert F. Siliciano
Clonal expansion of infected CD4+ T cells is a major mechanism of HIV-1 persistence and a barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 integration, and interaction with antigens. Here, we show that it is possible to link antigen responsiveness, the full proviral sequence, the integration site, and the T cell receptor β-chain (TCRβ) sequence to examine the role of recurrent antigenic exposure in maintaining the HIV-1 reservoir. We isolated CMV- and Gag-responding CD4+ T cells from 10 treated individuals. Proviral populations in CMV-responding cells were dominated by large clones, including clones harboring replication-competent proviruses. TCRβ repertoires showed high clonality driven by converging adaptive responses. Although some proviruses were in genes linked to HIV-1 persistence (BACH2, STAT5B, MKL1), the proliferation of infected cells under antigenic stimulation occurred regardless of the site of integration. Paired TCRβ and integration site analysis showed that infection could occur early or late in the course of a clone’s response to antigen and could generate infected cell populations too large to be explained solely by homeostatic proliferation. Together, these findings implicate antigen-driven clonal selection as a major factor in HIV-1 persistence, a finding that will be a difficult challenge to eradication efforts.

1 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NMNatalie F. McMyn
Natalie F. McMyn
JVJoseph Varriale
Joseph Varriale
EFEmily J Fray
Emily J Fray
CZCarolin Zitzmann
Carolin Zitzmann
HMHannah MacLeod
Hannah MacLeod
JSJanet M. Siliciano
Janet M. Siliciano
HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy (ART). The reservoir decays slowly over the first 7 years of ART (t1/2 = 44 months). However, whether decay continues with long-term ART is unclear. Recent integration site studies indicate gradual selection against inducible, intact proviruses, raising speculation that decades of ART might allow treatment interruption without viral rebound. Therefore, we measured the reservoir in 42 people on long-term ART (mean 22 years) using a quantitative viral outgrowth assay. After 7 years of ART, there was no long-term decrease in the frequency of inducible, replication-competent proviruses but rather an increase with an estimated doubling time of 23 years. Another reservoir assay, the intact proviral DNA assay, confirmed that reservoir decay with t1/2 of 44 months did not continue with long-term ART. The lack of decay reflected proliferation of infected cells. Most inducible, replication-competent viruses (79.8%) had env sequences identical to those of other isolates from the same sample. Thus, although integration site analysis indicates changes in reservoir composition, the proliferation of CD4+ T cells counteracts decay, maintaining the frequency of inducible, replication-competent proviruses at roughly constant levels over the long term. These results reinforce the need for lifelong ART.

20 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FSFrancesco R. Simonetti
Francesco R. Simonetti
JWJennifer A. White
Jennifer A. White
CTCamille Tumiotto
Camille Tumiotto
KRKristen D. Ritter
Kristen D. Ritter
MCMian Cai
Mian Cai
JSJanet D. Siliciano
Janet D. Siliciano
A scalable approach for quantifying intact HIV-1 proviruses is critical for basic research and clinical trials directed at HIV-1 cure. The intact proviral DNA assay (IPDA) is a novel approach to characterizing the HIV-1 reservoir, focusing on the genetic integrity of individual proviruses independent of transcriptional status. It uses multiplex digital droplet PCR to distinguish and separately quantify intact proviruses, defined by a lack of overt fatal defects such as large deletions and APOBEC3G-mediated hypermutation, from the majority of proviruses that have such defects. This distinction is important because only intact proviruses cause viral rebound on ART interruption. To evaluate IPDA performance and provide benchmark data to support its implementation, we analyzed peripheral blood samples from 400 HIV-1+ adults on ART from several diverse cohorts, representing a robust sample of treated HIV-1 infection in the United States. We provide direct quantitative evidence that defective proviruses greatly outnumber intact proviruses (by >12.5 fold). However, intact proviruses are present at substantially higher frequencies (median, 54/106 CD4+ T cells) than proviruses detected by the quantitative viral outgrowth assay, which requires induction and in vitro growth (∼1/106 CD4+ T cells). IPDA amplicon signal issues resulting from sequence polymorphisms were observed in only 6.3% of individuals and were readily apparent and easily distinguished from low proviral frequency, an advantage of the IPDA over standard PCR assays which generate false-negative results in such situations. The large IPDA dataset provided here gives the clearest quantitative picture to date of HIV-1 proviral persistence on ART. Significance Despite clinically effective antiretroviral therapy (ART), replication-competent HIV-1 persists as latent proviral DNA capable of rekindling viral replication when ART is stopped. To cure the infection, therapies are being developed to eliminate latent HIV-1. Accurate assays for intact or rebound-competent HIV-1 are important to this effort. We previously developed the intact proviral DNA assay (IPDA) as a more accurate and scalable assay for intact HIV-1 proviruses. Here we present IPDA analysis in a diverse cohort of 400 ART-treated individuals. We confirm that intact proviruses, although vastly outnumbered by defective proviruses, are present at significantly higher frequencies than previously detected by viral outgrowth assays. We also show that IPDA amplicon signal issues, observed in 6.3% of samples, result from sequence polymorphisms.